Costas Yannakou

Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2021

Benjamin W Teh, Daniel K Yeoh, Gabrielle M Haeusler, Costas K Yannakou, Shaun Fleming, Julian Lindsay, Monica A Slavin

Journal article  |  2021  |  INTERNAL MEDICINE JOURNAL

Antifungal prophylaxis can reduce morbidity and mortality from invasive fungal disease (IFD). However, its use needs to be optimis..

Characterisation of immune checkpoints in Richter syndrome identifies LAG3 as a potential therapeutic target

Clare Gould, Jennifer Lickiss, Yamuna Kankanige, Satwica Yemeni, Stephen Lade, Maher K Gandhi, Collin Chin, Costas K Yannakou, Diego Villa, Graham W Slack, John F Markham, Constantine S Tam, Niles Nelson, John F Seymour, Michael Dickinson, Paul J Neeson, David Westerman, Piers Blombery

Journal article  |  2021  |  BRITISH JOURNAL OF HAEMATOLOGY

Richter syndrome (RS), an aggressive lymphoma occurring in the context of chronic lymphocytic leukaemia/small lymphocytic lymphoma..

Advances in Frontline Management of Peripheral T-cell Lymphoma

Chathuri Abeyakoon, Carrie van der Weyden, Sean Harrop, Amit Khot, Michael Dickinson, Costas K Yannakou, H Miles Prince

Journal article  |  2021  |  CLINICAL LYMPHOMA MYELOMA & LEUKEMIA

Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphomas that are frequently associated with a poor prognosis. F..

Prolonged Lymphopenia and Infection Risk Is Mitigated By Antimicrobial Prophylaxis in Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Treated with Bendamustine /- Anti-CD20 Antibody: The Australasian Lymphoma Alliance Experience

Kate Manos, Masa Lasica, Andrew Grigg, Pietro R Di Ciaccio, Jonathan Wong, Usha Chandra Sekaran, Joel Wight, Zhong Goh, Hayden Jina, Llewyn Butler, Costas K Yannakou, Nada Hamad, Gareth P Gregory, Shane A Gangatharan, Tara Cochrane, Kristen Piper, Leonid Churilov, Eliza A Hawkes

Journal article  |  2020  |  Blood

Background: Bendamustine +/- anti-CD20 antibody is a highly effective regimen for iNHL. Though initially favoured f..

Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma

Michael S Khodadoust, Tatyana A Feldman, Dok Hyun Yoon, Costas K Yannakou, Dejan Radeski, Youn H Kim, Neha Mehta-Shah, Amit Khot, Ryan A Wilcox, Won Seog Kim, Steven M Horwitz, Joseph J Buggy, Andrew Hotson, Craig M Hill, Brian Munneke, Suresh Mahabhashyam, Richard A Miller, James W Janc, Mehrdad Mobasher

Conference Proceedings  |  2020  |  Blood

Background: Interleukin-2-Inducible T-Cell Kinase (ITK) is a Tec-family, non-receptor tyrosine kinase expressed in ..

Role of Haematopoietic Stem Cell Transplantation in Peripheral T-Cell Lymphoma

Chathuri Abeyakoon, Carrie van der Weyden, Sean Harrop, Amit Khot, Michael Dickinson, Costas K Yannakou, H Miles Prince

Journal article  |  2020  |  CANCERS

Peripheral T-cell lymphomas (PTCLs) are distinct pathological entities with clinical advancements lagging behind their B-cell lymp..

Characterization of the "Immune Evasion" Phenotype of Richter Syndrome and the Implications for Immune-Checkpoint Inhibitor Therapy

Clare Gould, Jennifer Lickiss, Yamuna Kankanige, Satwica Yerneni, John Markham, Costas K Yannakou, Diego Villa, Graham W Slack, Collin Chin, Constantine S Tam, Stephen Lade, Niles Elizabeth Nelson, Paul J Neeson, John F Seymour, Michael Dickinson, David Alan Westerman, Piers Blombery

Conference Proceedings  |  2019  |  BLOOD

Richter syndrome (RS) is the transformation of chronic lymphocytic leukemia (CLL) to a high-grade B-cell lymphoma and is associate..

An Update on Safety and Preliminary Efficacy of Highly Specific Bruton Tyrosine Kinase (BTK) Inhibitor Zanubrutinib in Combination with PD-1 Inhibitor Tislelizumab in Patients with Previously Treated B-Cell Lymphoid Malignancies

Constantine S Tam, Gavin Cull, Stephen Opat, Gareth P Gregory, Aichun Liu, Anna M Johnston, Weili Zhao, Fernando Roncolato, Sasanka M Handunnetti, H Miles Prince, Costas K Yannakou, Wenyu Li, Ted Shih, Xiaoping Zhang, Ken Wu, Yuan Liu, Jane Huang, Judith Trotman

Conference Proceedings  |  2019  |  BLOOD

Background: Zanubrutinib is an investigational, next-generation BTK inhibitor, designed to maximize BTK occupancy and minimize off..

Rapid and Durable Complete Remission of Refractory AITL with Azacitidine Treatment in Absence of TET2 Mutation or Concurrent MDS

Gareth P Gregory, Michael Dickinson, Costas K Yannakou, Jonathan Wong, Piers Blombery, Greg Corboy, Lev Kats, Tim ME Crozier, Beena Kumar, H Miles Prince, Stephen S Opat, Jake Shortt

Journal article  |  2019  |  HEMASPHERE

Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia

KD Cummins, SM Jane, S Ninkovic, A Bazargan, R Filshie, G Sutrave, M Hertzberg, A Scott, S Lane, CK Yannakou, D Ritchie, J D'Rozario, J Black, K Bavishi, A Wei

Journal article  |  2014  |  BLOOD CANCER JOURNAL